Form 4: NextCure Director Stephen W. Webster Acquires Stock Options
SEC Form 4 Filing
Director Stephen W. Webster acquired 18,700 stock options in NextCure, Inc. on June 20, 2024.
Summary
- Stephen W. Webster, a director of NextCure, Inc., acquired 18,700 stock options on June 20, 2024.
- The exercise price of these options is $1.5.
- The options vest fully on the earlier of June 20, 2025, and the date of the 2025 Annual Meeting of Stockholders.
- The options expire on June 19, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction, but a director acquiring options can be seen as a mildly positive signal.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of earliest transaction: Acquisition of stock options. |
| 06/20/2025 | Options vest fully on the earlier of this date and the date of the 2025 Annual Meeting of Stockholders. |
| 06/19/2034 | Expiration date of the stock options. |
| 06/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.